Albireo Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor, for the treatment of Alagille syndrome, a rare and life-threatening disease that affects the liver and has no approved pharmacologic treatment option. A4250 also holds Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of Alagille, and Orphan Drug designations fr...